top button
    Got Questions


Global IoT Summit 2018
Oct 31, 2018
The Leela Palace, Bangalore



    Connect to us
      Facebook Login
      Site Registration Why to Join

Facebook Login
Site Registration

Rheumatology Therapeutics Market Latest Update Scrutinized in New Research

0 votes
2 views

The global rheumatology therapeutics market is highly competitive and consolidated due to presence of strong players, finds Transparency Market Research (TMR). Some of the key players operating in the global rheumatology therapeutics market are AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Merck & Co., Inc., Amgen, Inc., Novartis AG, Janssen Biotech, Inc., Sanofi, Genentech, Inc., and Takeda Pharmaceutical. Among them, the companies such as AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., and Merck & Co., Inc. are accounts for the leading share in the global rheumatology therapeutics market.

TMR anticipated the global revenue of the rheumatology therapeutics market was registered in 2016 US$41.88 bn and expected to expand with a CAGR of 2.7% over the forecast period from 2017 to 2025 and expected to attain value of a US$ 52.96 bn by the end of 2025. On the basis of drug class, the segment biologic DMARDs has registered at the revenue of US$35.83 bn in 2016 is expected to rise at a 2.6% CAGR with this growth rate in a revenue of US$45.06 bn by 2025. This growth is attributable to high usage of Azathioprine, cyclosporine, cyclophosphamide, and methotrexate. On the basis of region, North America accounts for a leading share in the global rheumatology therapeutics market owing to rapid rise in the elderly population.

Request PDF Sample of Rheumatology Therapeutics Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1494

Rising Prevalence of Rheumatology Diseases to Boost Growth

Rheumatology diseases generally effects on the supporting and connecting structures and bones of the body such as joints, muscles, ligaments, tendons and some of the organs of body. It is characterized by effects on spine and inflammation of joints occurred in some of the symptoms of rheumatology disease. Early diagnosis and treatment on symptoms of rheumatology disease. Physicians generally prescribe disease-modifying anti-rheumatic drugs (DMARD’s) for treatment of rheumatologic disease. Rising prevalence of rheumatology diseases are boosting requirement of its treatments which is fuelling growth of the global rheumatology therapeutics market.

Additionally, technological advancements in pharmaceutical field coupled with increasing investments in healthcare industry for research and development activities. Rising trend for fitness globally which is expected to support the growth of rheumatology therapeutics market. Increasing expenditure on healthcare from mid-earing population is driving growth of the global rheumatology therapeutics market.

Buy Now “Rheumatology Therapeutics Market ” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1494&ltype=S

Availability of Alternatives for Rheumatology Therapeutics to Hamper Growth

However, launch of biosimilars is key factors hampering growth of the rheumatology therapeutics market. Rising demand for biosimilar products are crimping growth of the rheumatology therapeutics market. Additionally, patent expiry of well-known drugs used in the treatment of rheumatology diseases is hampering growth of the rheumatology therapeutics market. Nevertheless, increasing launches of novel biologics drugs and rising penetration of generic drugs are expected to drive growth of the market. Increasing approvals for new biologics such as Xeljanz are anticipated to account for high penetration which is likely to create opportunities in the global rheumatology therapeutics market.

More Trending Reports by Transparency Market Research –

Tissue Engineered Skin Substitutes Market: globenewswire.com/news-release/2019/01/23/1704315/0/en/Tissue-Engineered-Skin-Substitutes-Market-to-reach-around-US-3-87-billion-by-2023-TMR.html

Collagen Market: globenewswire.com/news-release/2019/05/15/1825247/0/en/Collagen-Market-to-Expand-at-a-CAGR-of-9-4-by-2023-Marine-Collagen-to-Gain-Maximum-Prominence-Says-TMR.html

posted 4 days ago by Bella Watson

  Promote This Article
Facebook Share Button Twitter Share Button Google+ Share Button LinkedIn Share Button Multiple Social Share Button

Related Articles
0 votes

Transparency Market Research (TMR) has published a new report titled, “Adult Malignant Glioma Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global adult malignant glioma therapeutics market was valued at US$ 1,349.6 Mn in 2017 and is projected to expand at a CAGR of 9.2% from 2018 to 2026. The global market is anticipated to witness steady growth owing to promising effective therapies in the pipeline for addressing the gaps in treatment.

Development of a promising drug to treat malignant glioma has proved difficult to date, with a number of promising candidates failing to achieve the desired test results in the past few years. However, technological advancements in the diagnosis of gliomas and analysis of its progression through various imaging modalities has improved the survival rates, thereby giving an enhanced edge for rapid evaluation of efficacy of several pipeline drugs. North America and Europe are projected to dominate the global adult malignant glioma therapeutics market during the forecast period, primarily due to the significant reimbursement coverage. The market in Asia Pacific is expected to expand at a significant CAGR from 2018 to 2026.

Rise in Patient Population and Expedited Drug Discovery Process to Drive Market

According to the World Health Organization, globally, an estimated 245,000 cases of brain and nervous system tumors are reported each year. Glioblastoma multiforme is the most common and the most lethal of these tumors. Gliomas are categorized under rare diseases; however, the incidence rate across the globe has witnessed steady rise in the last decade. Adoption of novel drug discovery technologies, such as high-throughput screening and TCGA, has reduced the overall drug discovery time and the cost of drug development. This is attributed to rise in the number of players participating in new product development and launches in various therapy areas, including glioma. These factors are likely to drive the global adult malignant glioma therapeutics market during the forecast period.

Request PDF Sample of Adult Malignant Glioma Therapeutics Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13211

Glioblastoma Multiforme Segment to Continue to Dominate Market

In terms of type, the global adult malignant glioma therapeutics market has been classified into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. The glioblastoma multiforme segment is projected to hold dominant share of the global market during the forecast period, owing to gradual rise in adoption of novel drug therapies, rapidly increasing patient population, surge in investment in research and development of targeted therapies to improve survival rates, and significant improvements in hospital infrastructure in high growth potential developing countries.

Targeted Drug Therapy to be Major Segment with Above-average Growth Rate

In terms of therapy, the global adult malignant glioma therapeutics market has been divided into chemotherapy, targeted drug therapy, and radiation drug therapy. The chemotherapy segment has been classified into temozolomide, bevacizumab, carmustine, and others. The targeted drug therapy segment has been categorized into EGFR inhibitors, other monoclonal antibodies, and others. The targeted drug therapy segment dominated the global adult malignant glioma therapeutics market in 2017 owing to high cost of therapy and high patient preference. The segment is also likely to register above-average growth rate due to development of new combination therapies with novel technologies such as gene therapy, nucleic acid therapies, lytic viruses, stem cells, nanoparticles, and others, and rise in focus on reducing cost of care to address the demand for affordable care.

High Adoption of Advanced Therapeutics in Developed Markets

North America and Europe held over 60% share of the global adult malignant glioma therapeutics market in 2017. This is attributed to higher cost of therapy than that in developing regions, high adoption rate of technologically-advanced products, greater reimbursement coverage that ensures return on investment for emerging market entrants, and provision of orphan drug designation that aids in the process of drug approval. Developing countries such as China and India are likely to offer significant opportunities during the forecast period owing to above average incidence rate of malignant gliomas, significant geriatric population, rise in awareness about early diagnosis and treatment compliance, and improving health care infrastructure. The market in these countries is highly price sensitive and regulated by a government cap on the prices of therapeutics.

Buy Now “Adult Malignant Glioma Therapeutics Market ” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=13211&ltype=S

Highly Consolidated Market with Low to Moderate Risk of New Entrants

The global adult malignant glioma therapeutics market is highly consolidated, with top three players accounting for more than 65% share in terms of revenue in 2017. These companies are projected to dominate the global market during the forecast period. However, the market is also likely to witness some novel drug launches with innovative mechanism of action by emerging players during the early forecast period. The report profiles leading players operating in the global adult malignant glioma therapeutics market such as F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Arbor Pharmaceuticals, Pfizer, Inc., AbbVie, Inc., Amgen, Inc., Bristol-Myers Squibb Company, Sun Pharmaceuticals Ltd., Teva Pharmaceutical Industries Limited, and Emcure Pharmaceuticals Limited.

0 votes

Blood Pressure Monitoring Devices & Accessories Market: Introduction

Transparency Market Research has published a new report titled, ‘Global Blood Pressure Monitoring Devices & Accessories Market’. According to the report, the global blood pressure monitoring devices & accessories market was valued at ~US$ 1.9 Bn in 2018 and is projected to expand at a CAGR of ~7% from 2019 to 2027.

The medical term for high blood pressure is hypertension. Blood pressure is considered to be normal under a systolic value of 140 mmHg and under a diastolic value of 90 mmHg. A blood pressure monitoring device reads blood pressure automatically based on variations in the volume of blood in the arteries. Systolic and diastolic are terms used to depict or interpret blood pressure. The blood pressure is measured in terms of millimeters of mercury (mmHg). The three stages of hypertension are prehypertension (from 120-139 over 80-90), stage 1 (from 140-159 over 90-99), and stage 2 (from 160 and above over 100 and above).

Blood Pressure Monitoring Devices & Accessories Market: Major Segments

In terms of device, the global blood pressure monitoring devices & accessories market has been segmented into sphygmomanometers, automatic blood pressure monitors, ambulatory blood pressure monitors, blood pressure transducers, and blood pressure instrument accessories. Sphygmomanometers have been categorized into mercury sphygmomanometers, aneroid sphygmomanometers, and digital sphygmomanometers. Blood pressure transducers has been classified into disposable and reusable.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1630

Blood pressure instrument accessories have been split into blood pressure cuffs, and bladders, bulbs, and valves. The automatic blood pressure monitors segment is projected to dominate the global market during the forecast period, owing to increase in usage in different types of surgeries for different indications. User-friendliness and safe application are the major advantages of these devices. The segment held significant share of the global blood pressure monitoring devices & accessories market in 2018. The automatic blood pressure monitors segment is anticipated to expand at a moderate CAGR between 2019 and 2027, owing to rise in surgeries and adoption rate of self-serving diagnostic tools.

Sphygmomanometers are the other most preferred blood pressure monitors, as these are cost-effective and offer accurate readings. Growth of the sphygmomanometers segment is likely to be stable owing to decline in usage of mercury sphygmomanometers, introduction of large number of aneroid sphygmomanometers in the market, and rise in digitalization in the readings of blood pressure monitors. The blood pressure transducers and blood pressure instrument accessories segments are anticipated to witness moderate growth during the forecast period. High accuracy of blood pressure transducers, increase in the geriatric population, and favorable trade regulations in the developing countries are the major factors expected to propel the blood pressure transducers and blood pressure instrument accessories segments during the forecast period.

Based on end user, the global blood pressure monitoring devices & accessories market has been divided into hospitals, ambulatory surgical centers, clinics, home care settings, and others. The home care settings segment captured the largest market share in 2018, owing to the availability of trained & qualified personnel and favorable reimbursement structure.

The segment is expected to expand at the highest CAGR during the forecast period, attributed to the miniaturization of devices and rise in need & demand for self-testing devices by patients. Increase in the geriatric population and improvements in healthcare facilities in developing countries are anticipated to propel the clinics segment during the forecast period. However, rise in need & demand for blood pressure kiosks at public places (gym, airports, colleges, etc.) and government funding to boost the production of blood pressure monitors are likely to augment the ambulatory surgical centers and others segments during the forecast period.

Buy Now Blood Pressure Monitoring Devices & Accessories Market Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1630&ltype=S

Blood Pressure Monitoring Devices & Accessories Market: Prominent Regions

North America held major share of the global blood pressure monitoring devices & accessories market in 2018. Highly structured health care industry, presence of key players, and growth strategies of these players are the major factors driving the market in the region. Rise in awareness about the benefits of surgeries and procedures and increase in healthcare expenditure also contribute to the growth of the market in North America.

Asia Pacific held the second largest share of the global blood pressure monitoring devices & accessories market in 2018. Growth of the blood pressure monitoring devices & accessories market in the region can be attributed to rise in prevalence of chronic diseases and well-developed healthcare sector in the region. The market in Asia Pacific is expected to grow at a rapid pace during the forecast period. Increase in number of people with cardiovascular diseases, product approvals, and rise in awareness about cardiovascular diseases are factors anticipated to fuel the growth of the blood pressure monitoring devices & accessories market in the region.

Blood Pressure Monitoring Devices & Accessories Market: Key Players

Key players are expanding their footprint to strengthen their positions in the global blood pressure monitoring devices & accessories market. Increase in population with hypertension offers lucrative opportunities to key players to increase their share in the blood pressure monitoring devices & accessories market. Hence, manufacturers are engaging in new product development, collaborations, and distribution to gain market share.

Leading players operating in the global blood pressure monitoring devices & accessories market include Omron Healthcare, Inc., Koninklijke Philips N.V., Schiller AG, American Diagnostic Corporation, SPENGLER, Spacelabs Healthcare, Withings SA, Welch Allyn, Inc., SunTech Medical, Inc., A&D Medical, and GE Healthcare.

More Trending Reports by Transparency Market Research –

ePharmacy Market: prnewswire.com/news-releases/epharmacy-market-to-reach-us128-billion-by-2023-transparency-market-research-560938961.html

Canada Home Healthcare Market: prnewswire.com/news-releases/canada-home-healthcare-market-set-to-reach-us1894-bn-by-the-end-of-2020-transparency-market-research-565741581.html

0 votes

The global glioblastoma multiforme treatment market is anticipated to rise significantly owing to key players adopting competitive strategies such as merger and acquisitions for marketing. According to a report by Transparency Market Research, the key players in the global glioblastoma multiforme treatment are adopting strategies such as development of biological drugs that helps in reducing the side effects in the patients which are caused due to consuming chemotherapeutic agents and immunosuppressant along with multiple therapies.

The prominent players in the market are also collaborating with diagnostic laboratories so as to increase awareness level of the population in regards to the availability of options for treatment for the invasive diseases.

Some of the key players operating in the global glioblastoma multiforme market are Celldex Therapeutics, Inc., Abbvie, Inc., Brostol-Myers Squibb Co., F.Hoffman La Roche, and Exellixis, Inc. During 2013, F.Hoffman La Roche was the most efficient and promising source of glioblastoma multiforme treatment all because of “brain shuttle” which was the company’s novel drug delivery system.

Request PDF Sample of Glioblastoma Multiforme Treatment Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=4807

The global glioblastoma multiforme treatment market is expected to rise at a healthy CAGR of 11.4% during the forecast period of 2014 to 2022. The global market is expected to attain a valuation of $US0.91 bn by the end of 2022. The global glioblastoma multiforme product segment is led by bevacizumab product and is expected to rise in demand during the forecast period as it is more efficient than temozolomide. Geographically, the glioblastoma multiforme treatment market is led by North America. This region is consuming larger share in the market is expected to dominate the global market during the forecast period.

Rise in Awareness Regarding Cancer and Novel Therapies to Boost Global Glioblastoma Multiforme Market

The global glioblastoma multiforme treatment market is rising rapidly owing to increasing geriatric population. Rise in awareness about the brain tumor itself is generating demand for the glioblastoma multiforme treatment market. Various organizations across the globe are spreading awareness about the introduction of novel therapies thus, boosting the growth of market. Rise of modern techniques for diagnosis and rapid development of drug delivery technologies are likely to supplement the growth of the market. Increasing support from government to conduct research and development across the globe is adding fuel to the market.

Development of healthcare infrastructure is one of the reasons for market growth. The unmet medical needs require desperate novel treatment strategies thus, generating demand for the market. The glioblastoma multiforme treatment pipeline include a mix of immunotherapy, small molecules, biological therapeutics and other types of therapeutics that makes it ideal for treatment of disease. Advanced introduced in molecular biology and gene technology also has the potential to provide lucrative novel possibilities for effective treatment of diagnosed patients.

Buy Now “Glioblastoma Multiforme Treatment Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=4807&ltype=S

Recurrence of Disease Likely to Hamper Market Growth

The global glioblastoma multiforme treatment market is anticipated to face certain restrains in the market that might hamper the growth of the market. The current FDA approved treatments are likely to cause neurotoxicity in patients which might stagger the growth of market. This treatment is not resistance against DNA modifying agents thus, hampering its growth in the market. The migration of malignant cells inside the adjacent brain tissues increasing the complexity of surgery is also affecting the market.

The treatment options lack efficiency as the mortality rate is characterized by rapid growth and poor survival rates. Survival rates of glioblastoma is 8.7% even after glioblastoma multiforme treatment being in the healthcare sector since last few years. The modalities have worked little to decrease the overall mortality rate of patients. Recurrence of the disease, invasiveness of GBM, and resistance of glioma stem cell against conventional modalities are other potential factors that will hamper the growth of the global glioblastoma multiforme treatment market.

0 votes

The global pain management devices market features an increasingly competitive landscape marked by rising level of competition among its players. A plethora of players in the market are vying for higher stakes. To this end, they are focusing on unveiling various types of pain management devices with novel technologies in order to reap competitive benefits. Several prominent players have been engaged in expanding their portfolio to consolidate their shares in the global pain management devices market. Rising investments on research and development activities is likely to up the intensity of competition in the pain management devices market in the coming years.

Some of the top players operating in the global pain management devices market are Bio-Medical Research (BMR) Ltd., Halyard Health, Stryker Corp, Baxter International Inc., and Boston Scientific Corp.

The global pain management devices market stood US$3.75 billion in 2016 and is projected to touch a valuation of US$6.28 billion by the end of 2023. This represents a CAGR of 7.6% during the forecast period of 2015–2023.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1143

Among the various types of products, neurostimulation devices held the leading share in 2015 and is likely to hold its sway throughout the assessment period. The prevalence of high-impact chronic pain conditions such as those by musculoskeletal is expected to bolster the uptake in the next few years.

Of the key regional markets for pain management devices, North America has been consistently garnering substantial shares over past few years. The regional market for pain management device is anticipated to continue holding prominent shares in the near future, as well. The growth is increasingly fueled by rising incidence sports-related injuries that need pain management devices.

Prevalence of Sports-Related Musculoskeletal Injuries offers Robust Boost

The rising demand for better management technologies among patient populations world over is a key factor driving the pain management devices market. Globally rising opioid epidemic has offered an attractive impetus to the demand for pain management technologies.

Rising elderly populations, especially in developing and developed nations, has contributed to the prevalence of chronic pain. This is a notable trend bolstering the demand for pain management devices. In numerous countries, the rising incidence of sports and recreation-related injuries leading to hospitalization is bolstering the demand for pain management devices. In particular, the demand is increasingly receiving solid boost from the prevalence of sports-related musculoskeletal injuries in developed countries.

The global pain management devices market is likely to get attractive impetus from several government initiatives and favorable regulatory landscape. In developed nations, reimbursements for spinal cord stimulation devices for patient populations have been fueling the market’s growth in developed countries.

Buy Now @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1143&ltype=S

Demand for Better Pain Management Devices for Neuropathic Pain creates Substantial Prospects

The advent of novel pain management devices has created new, exciting avenues in the global market. Increasing pace of commercialization of such devices in recent years has catalyzed rapid market’s expansion.

The global pain management devices market is likely to witness setbacks on account of low level of patient awareness and the high cost of these devices. Moreover, potential side-effects with certain pain management devices have dampened the uptake. The risk of side effects of skin erosion and surgical site infection associated with neurostimulation implants is a case in point.

Nevertheless, the rising incidence of neuropathic pain world over is making room for several lucrative avenues for medical device manufacturers. They are expanding their pipeline of products. Moreover, the rising awareness about the ill effects of prescription pain killers kindles patients’ interest in technologically-advanced pain management devices.

0 votes

The vendor landscape of the global non-small cell lung cancer therapeutics market features the presence of a number of players, but was dominated by Genentech, a Roche company, which accounted for nearly 36% of the overall market in 2014, observes a recent report by Transparency Market Research (TMR). The market is marked with a moderate level of competition and focus on the development of new and more effective varieties of drugs has increased from companies anticipating a better grip on the market. Strategic collaborations with the view of expanding geographical outreach and product portfolios is also a key strategy adopted by companies operating in the global non-small cell lung cancer therapeutics.

Some of the leading companies operating in the market are Novartis AG, Bristol-Myers Squibb, Celgene Corporation, AstraZeneca plc, Pfizer, Inc., Boehringer Ingelheim, and Eli Lilly and Company.

According to the report, the global non-small cell lung cancer therapeutics market will rise to a valuation of US$15.1 bn by 2023.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

Asia Pacific Promising Excellent Growth Opportunities

Geographically, the market in Asia Pacific is expected to emerge as one of the leading contributors of revenue to the global market, thanks to the rising awareness regarding cancer and the active role of governments in the region in supporting the treatment of lung cancer through subsidized treatment and medicines in public healthcare centers. The region will continue to remain one of the most lucrative regional market for the field of non-small cell lung cancer therapeutics owing to the rising prevalence of lung cancer.

Based on drugs, the segment of angiogenesis inhibitors is expected to dominate in terms of demand as well as revenue contribution to the global market. This can be attributed to its effectiveness and the increased adoption of targeted therapies in a number of regional markets. The segment is expected to rise to a valuation of US$2,020.4 mn by 2023.

Rich Pipeline of Drugs and Continuous R&D Efforts Open Up Promising Growth Avenues for Market

The rising prevalence of lung cancer globally is naturally the leading cause driving the market for non-small cell lung cancer therapeutics. The increased understanding regarding the various changes observed in non-small cell lung cancer cells that help them further grow is leading to the development of newer drug classes for targeting the changes specifically. Active R&D efforts in this field are also proving beneficial for the overall development of the global non-small cell lung cancer therapeutics market.

Enquiry for Discount @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=504

Thanks to continuous efforts and continuous influx of funds into R&D from market players, the market has seen the development of a rich pipeline of innovative drug classes in the past few years. Innovative new generation drugs such as Alecensa (alectinib), which is development by Genentech for the treatment of ALK-positive non-small cell lung cancer, are being approved by a number of drug approval bodies for marketing across the globe. This scenario has also helped a number of new players foray into the market, thus improving the market’s growth prospects.

However, as several highly anticipated drugs are still in the early stages of pipeline, which may take some more time to hit the market, there is a level of uncertainty regarding returns on investment. Moreover, resistance of several cancers to targeted therapies also poses challenges to the further expansion of the market to a certain degree.

More Trending Reports by Transparency Market Research –

Hearing Aids Market: prnewswire.com/news-releases/hearing-aids-market-increasing-prevalence-of-hearing-loss-worldwide-augments-product-demand-says-tmr-300857268.html

Viral Vector and Plasmid DNA Manufacturing Market: globenewswire.com/news-release/2019/04/30/1812834/0/en/Viral-Vector-and-Plasmid-DNA-Manufacturing-Market-is-anticipated-to-surpass-US-2-Billion-by-2027-TMR.html

...